Ruiyu Han

Dr. Ruiyu Han


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
WPWenshuai Pang
Wenshuai Pang
XTXin Tian
Xin Tian
FBFan Bai
Fan Bai
RHRuiyu Han
Ruiyu Han
JWJuan Wang
Juan Wang
LXLingxiao Xing
Lingxiao Xing
Pim-1 kinase is a proto-oncogene and its dysregulation contributes to tumorigenesis and progression of a variety of malignancies. Pim-1 was suggested as a therapeutic target of cancers. The functional relevance of Pim-1 and the mechanism underlying its dysregulation in lung tumorigenesis remained unclear. This study aimed to investigate if Pim-1 has important functions in non-small-cell lung cancer (NSCLC) by: 1) evaluating the clinicopathologic significance of Pim-1 through analysing its expression in 101 human NSCLCs tissues using quantitative PCR, Western Blot and immunohistochemical studies, 2) determining its role in NSCLC and drug resistance using in vitro assays, and 3) investigating the regulatory mechanism of Pim-1 dysregulation in lung tumorigenesis. Pim-1 was upregulated in 66.2% of the lung tumor tissues and its expression was significantly related to advanced stage (P = 0.019) and lymph node metastasis (P = 0.026). Reduced Pim-1 expression suppressed NSCLC cell growth, cell cycle progression and migration in vitro. Pim-1 was a novel target of miR-486-5p determined by luciferase report assay, and ectopic miR-486-5p expression in cancer cells reduced Pim-1 expression. Furthermore, eukaryotic translation initiation factor 4E (eIF4E) controlled the synthesis of Pim-1 in NSCLC cells, and its expression was positively associated with that of Pim-1 in NSCLC tissue specimens (r = 0.504, p < 0.001). The downregulated miR-486-5p and upregulated eIF4E in NSCLC cells led to the overexpression of Pim-1 by relieving the inhibitory effect of the 3′-UTR or 5′-UTR of Pim-1 mRNA, respectively. Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. Pim-1 kinase could be a critical survival signaling factor in NSCLC, and regulated by miR-486-5p and eIF4E. Pim-1 kinase may provide a potential target for diagnosis and treatment for lung cancer.

3 August 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
XWXinshi Wang
Xinshi Wang
HHHai-Jun He
Hai-Jun He
XXXi Xiong
Xi Xiong
SZShuoting Zhou
Shuoting Zhou
WWWen-Wen Wang
Wen-Wen Wang
CXCheng-Long Xie
Cheng-Long Xie
Mitochondria in neurons generate adenosine triphosphate (ATP) to provide the necessary energy required for constant activity. Nicotinamide adenine dinucleotide (NAD+) is a vital intermediate metabolite involved in cellular bioenergetics, ATP production, mitochondrial homeostasis, and adaptive stress responses. Exploration of the biological functions of NAD+ has been gaining momentum, providing many crucial insights into the pathophysiology of age-associated functional decline and diseases, such as Alzheimer’s disease (AD). Here, we systematically review the key roles of NAD+ precursors and related metabolites in AD models and show how NAD+ affects the pathological hallmarks of AD and the potential mechanisms of action. Advances in understanding the molecular roles of NAD+-based neuronal resilience will result in novel approaches for the treatment of AD and set the stage for determining whether the results of exciting preclinical trials can be translated into the clinic to improve AD patients’ phenotypes.

19 July 2021 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
JCJie Chen
Jie Chen
HHHai-Jun He
Hai-Jun He
QYQianqian Ye
Qianqian Ye
FFFeifei Feng
Feifei Feng
WWWen-Wen Wang
Wen-Wen Wang
CXChenglong Xie
Chenglong Xie

1 December 2015 in Human Pathology
Verified
Journal Article
Closed access
ZWZhenzhou Wu
Zhenzhou Wu
FBFan Bai
Fan Bai
LFLiyun Fan
Liyun Fan
WPWenshuai Pang
Wenshuai Pang
RHRuiyu Han
Ruiyu Han
LXLingxiao Xing
Lingxiao Xing